GENERAL INFORMATION
The Cancer Therapy & Research Center (CTRC) Institute for Drug Development at the University of Texas Health Science Center at San Antonio (UT Health Science Center) invites you to the 15th Annual Practical Applications of New Agents in Oncology. The Friday sessions will be held at the Cancer Therapy & Research Center, 7979 Wurzbach Road, San Antonio, TX in the Mabee Conference Room, 4th Floor Grossman Building and the Saturday sessions will be held at the adjacent Greehey Children’s Cancer Research Institute, 8403 Floyd Curl Drive, San Antonio. The conference begins Friday, February 7 and features an expanded nursing session with content of interest to all professionals and continues on Saturday, February 8. Don’t miss the Friday evening reception where you can network with colleagues, invited speakers, and industry representatives. The reception will be held at 6:30pm at CTRC, 7979 Wurzbach Road, San Antonio, TX in the Mabee Conference Room, 4th Floor Grossman Building.

OVERVIEW
Cancer remains a leading cause of death in the country. Educating the healthcare professional about newly available agents in oncology is crucial.

The CTRC at The UT Health Science Center has hosted this event since 1998. As a National Cancer Institute-designated cancer center, one of the only four in the state of Texas, the CTRC is recognized for scientific excellence and extensive resources focused on cancer. CTRC’s total patient care system – that consists of a breakthrough research, state-of-the-art technology, multidisciplinary clinical care delivered through a team of world-class physicians, laboratory scientists and other medical professionals – allows it to seamlessly translate the latest research directly to patients.

As a result of attending the conference, attendees will be able to cite the results of clinical studies of new anticancer agents and current dilemmas, with a principal focus on discerning the role or eventual role of new therapies in the clinical practice of oncology. They will also be able to describe the procedure for determining incorporation of new anticancer agents and therapeutics into clinical practice.

PROGRAM GOALS
To provide the most up-to-date treatment and care to patients with cancer; information regarding new agents must be spread to the healthcare professional community. The Practical Applications New Agents in Oncology conference disseminates this information to the healthcare professional who in turn will use it to provide the highest quality cancer treatment.

This conference will focus on the large number of new anticancer agents and related supportive therapeutics that have been approved over the last several years, as well as those that will likely be approved. Several world renowned and local speakers will discuss the incorporation of these agents into standard clinical practice, providing guidance to front-line clinicians, nurses and pharmacists regarding current or projected appropriate use of these therapeutics. Topics will include both early and late stages of various malignancies, and combined modality therapies (chemotherapy + surgery + radiotherapy) whenever pertinent.

EDUCATIONAL OBJECTIVES
As a result of participating in this continuing medical education activity, healthcare professionals will be able to:

• Cite the results of clinical studies of new anticancer agents and current dilemmas, with a principal focus on discerning the role or eventual role of new therapies in the clinical practice of oncology.
• Describe the procedure for determining the incorporation of new anticancer agents and therapeutics into clinical practice.
• Discuss the management of adverse effects associated with cancer treatment.
• Choose the appropriate treatment options for patients with cancer based on clinical data and individual patient characteristics.
• Discuss the novel agents in development for the treatment of cancer.

WHO SHOULD ATTEND?
The conference has an attractive case-based format and represents national points of view, making it a stimulating meeting for primary care and oncology clinicians, physicians, nurses, nurse practitioners, physician assistants, other health professionals, and medical students. Continuing Education credits will be provided for Medical, Nursing and Pharmacy.

DATE
February 7-8, 2014

HOTEL INFORMATION
Omni San Antonio Hotel at the Colonnade
9821 Colonnade Boulevard San Antonio, TX 78230
210-691-8888
http://www.omnihotels.com/FindAHotel/SanAntonio.aspx
Room Rate: $106 (plus tax) per night.
Please make your reservations directly with the hotel. Be sure to ask for the CTRC IDD Room Block to qualify for the special rate. These rooms will be held for conference attendees until Friday, January 17, 2014. After that date, the availability of rooms and conference rates cannot be guaranteed.
ACCREDITATION
Continuing Medical Education
The UT Health Science Center School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The UT Health Science Center School of Medicine designates this live educational activity for a maximum of 12.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

COURSE DIRECTOR
Steven Weitman, M.D., Ph.D.
Director Institute for Drug Development

COURSE CO-DIRECTORS
Gerardo Medina, RN, CCRP
Director Research Nursing
Institute for Drug Development

Kim Wright
Project Coordinator
CTRC at the UT Health Science Center

Rachel Ortiz-Wong
Project Coordinator
CTRC at the UT Health Science Center

PLANNING COMMITTEE
Michelle Davis
Director, Clinical Trials Office
Institute for Drug Development

Anand Karnad, M.D.
Professor
Hematology/Oncology
CTRC at the UT Health Science Center

Kevin Kelly, M.D.
Assistant Professor
Hematology/Oncology
CTRC at the UT Health Science Center

Steffan Nawrocki, Ph.D.
Co-Director, Preclinical Research, Institute for Drug Development

Laura Alvarado, RN, MSN, NEA-BC
Director
Continuing Nursing Education
UT Health Science Center at San Antonio School of Nursing

GUEST FACULTY
Harold J. Burstein, M.D., Ph.D.
Associate Professor of Medicine, Dana-Farber Cancer Institute
Boston, MA

Saad A. Khan, M.D.
Assistant Professor Division of Hematology and Oncology, UT Southwestern Medical Center
Dallas, TX

Alan F. List, M.D.
President and CEO
Moffitt Cancer Center
Tampa, FL

Rowena Schwartz, Pharm.D., BCOP
Sr. Director, Clinical Content & Services
McKesson Specialty Health
The Woodlands, TX

Ian F. Tannock, M.D., Ph.D., DSc.
Professor of Medical Oncology, Princess Margaret Cancer Centre
Toronto, Canada

LOCAL FACULTY
G. Richard Holt, M.D., D BE.
Bioethics Professor Emeritus
Otolaryngology
UT Health Science Center

Deva Mahalingam, M.D., Ph.D.
Assistant Professor
Hematology/Oncology
CTRC at the UT Health Science Center

Laeeq A. Malik, M.D.
Fellow, Institute for Drug Development
Hematology/Oncology
CTRC at the UT Health Science Center

Alex V. Mejia, M.D.
Fellow, Institute for Drug Development
Hematology/Oncology
CTRC at the UT Health Science Center

Amelie G. Ramirez, M.P.H., Dr.P.H.
Professor of Epidemiology & Biostatistics
Director, Institute for Health Promotion Research
UT Health Science Center

John Sarantopoulos, M.D.
Assistant Professor
Hematology/Oncology
CTRC at the UT Health Science Center

Robert S. Svatek, M.D.
Assistant Professor
Division of Urology
UT Health Science Center

Jodi L. Taraba, Pharm.D., MSc.
Supervisor, IDS Pharmacy
CTRC at the UT Health Science Center

Steven Weitman, M.D., Ph.D.
Professor and Director, Institute for Drug Development
CTRC at the UT Health Science Center
### Friday, February 7, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-3:00pm</td>
<td>Registration/Visit Exhibits</td>
</tr>
<tr>
<td>1:00-1:50pm</td>
<td>Health Disparities&lt;br/&gt;Amelie G. Ramirez, M.P.H., Dr.P.H.</td>
</tr>
<tr>
<td>1:50-2:00pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>2:10-3:00pm</td>
<td>Ethical Conduct of Clinical Research in Medical and Surgical Oncology&lt;br/&gt;Richard Holt, MD, D BE.</td>
</tr>
<tr>
<td>3:00-3:10pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>3:20-4:10pm</td>
<td>Repurposing of Drugs for Use in Oncology&lt;br/&gt;Jodi L. Taraba., Pharm.D., MSc.</td>
</tr>
<tr>
<td>4:10-4:20pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>4:25-5:15pm</td>
<td>Medication Management: Opportunities to Optimize Care with Oral/Self-Administered Medications in Oncology&lt;br/&gt;Rowena Schwartz, Pharm.D., BCOP</td>
</tr>
<tr>
<td>5:15-5:25pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>6:30 – 8:00pm</td>
<td>Meet the Professor Reception</td>
</tr>
</tbody>
</table>

### Saturday, February 8, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-8:00am</td>
<td>Registration/Breakfast/Visit Exhibits</td>
</tr>
<tr>
<td>8:00-8:05am</td>
<td>Welcome&lt;br/&gt;Steve Weitman, M.D., Ph.D.</td>
</tr>
<tr>
<td>8:05-8:55am</td>
<td>New Treatments for MDS&lt;br/&gt;Alan List M.D.</td>
</tr>
<tr>
<td>8:55-9:05am</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>9:10-9:45am</td>
<td>Hematologic Cancers-What is New?&lt;br/&gt;Alex Mejia, M.D.</td>
</tr>
<tr>
<td>9:45-9:55am</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>10:00-10:50am</td>
<td>Advances in Breast Cancer Therapies&lt;br/&gt;Harold Burstein, M.D., Ph.D.</td>
</tr>
<tr>
<td>10:50-11:00am</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>11:00-11:15am</td>
<td>Break</td>
</tr>
<tr>
<td>11:15-11:50am</td>
<td>New Treatments for Colorectal Cancer&lt;br/&gt;Laeeq Malik, M.D.</td>
</tr>
<tr>
<td>11:50-12:00am</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>12:00-12:35pm</td>
<td>New Approaches to Liver Cancer&lt;br/&gt;Deva Mahalingam, M.D., Ph.D.</td>
</tr>
<tr>
<td>12:35-12:45pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>12:45–1:45pm</td>
<td>Lunch/Visit Exhibits</td>
</tr>
</tbody>
</table>

### Moderator: Anand Karnad, M.D.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:45-2:35pm</td>
<td>Exciting News for Prostate Cancer&lt;br/&gt;Ian Tannock, M.D., Ph.D.</td>
</tr>
<tr>
<td>2:35-2:45pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>2:45-3:20pm</td>
<td>Renal Cell Carcinoma&lt;br/&gt;John Sarantopoulos, M.D.</td>
</tr>
<tr>
<td>3:20-3:30pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>3:30-3:45pm</td>
<td>Break/Visit Exhibits</td>
</tr>
</tbody>
</table>

### Moderator: John Sarantopoulos, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45-4:20pm</td>
<td>Novel Therapeutic Approaches to Manage Bladder Cancer&lt;br/&gt;Robert Svatek, M.D.</td>
</tr>
<tr>
<td>4:20:4:30pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>4:30-5:05pm</td>
<td>A New Era in Thyroid/Head and Neck Cancer&lt;br/&gt;Saad Khan, M.D.</td>
</tr>
<tr>
<td>5:05-5:15pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>5:30pm</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>